Recently, in 665 patients with ATTR-CM (either variant or wild-type ATTR amyloidosis, 89% were wild-type), vutrisiran, a subcutaneously administered RNA interference therapeutic agent that inhibits hepatic synthesis of both wild-type and variant TTR messenger RNA, led to a lower risk of all-cause death and recurrent CV events (defined as hospitalizations for CV causes or urgent visits for HF) compared with the placebo (HR in the overall population, 0.72; 95% CI 0.56 to 0.93; p = 0.01). The gene discussed is TTR; the disease is hydrops fetalis.